Image: Healthcare ReadersHealthcare News Roundup: June 7-20, 2026 FDA, NHS, Biotech
β’ The FDA has granted a new indication for the drug Tzield, expanding its use to patients who have already progressed to Stage 3 type 1 diabetes. β’ This latest approval aims to preserve residual beta cell function, building on previous expansions in April 2026 that extended the drug's use to children as young as one year old. β’ The decision was based on the PROTECT trial, which demonstrated a statistically significant effect on C-peptide, a surrogate endpoint used to predict clinical benefit.
healthcarereaders.com



